Optic neuritis

01OverviewDefinition, clinical context and the essential points that orientate the chapter.

Optic neuritis is inflammation of the optic nerve, often involving damage to myelin and impairment of signal transmission from the retina to the brain. The patient may describe central blur, dimming, washed-out colours or reduced contrast rather than complete blindness. Symptoms commonly develop over hours to several days and are often accompanied by discomfort on moving the eye. Ask what has changed in each eye separately, whether colours appear different between eyes and whether the patient has had previous visual or neurological episodes.

The clinical pattern supports a working diagnosis but does not prove the underlying cause. A young adult with unilateral painful loss and a relatively normal-looking disc differs from a patient with profound bilateral loss, striking swelling, repeated attacks or poor recovery. These atypical findings can accompany disorders requiring more intensive and urgent treatment. Likewise, painless abrupt loss in an older patient should prompt careful consideration of ischaemia and giant-cell arteritis rather than automatic use of an optic-neuritis label.

For typical demyelinating episodes, visual recovery often begins over the following weeks, and high-dose corticosteroids can accelerate recovery without guaranteeing a better final visual outcome. This does not mean all cases can be observed without specialist assessment. Treatment decisions incorporate severity, the fellow eye, occupational function, medical risk and the likelihood of a different inflammatory disorder. Neurological evaluation remains important even after vision improves, because an isolated episode can lead to assessment for multiple sclerosis or another disease requiring longer-term management.

Key points

Typical optic neuritis produces subacute visual reduction, impaired colour or contrast perception and pain that often increases with eye movement.
A relative afferent pupillary defect supports unilateral or asymmetric optic-nerve dysfunction, but its absence does not exclude symmetric bilateral disease.
The optic disc can look normal when inflammation lies behind the globe; a normal fundus does not establish normal optic-nerve function.
Optic neuritis can be associated with multiple sclerosis, neuromyelitis optica spectrum disorder, MOG-antibody-associated disease or other inflammatory and infectious causes.
MRI of the brain and appropriately imaged orbits helps assess the optic nerve, alternative pathology and associated central nervous system lesions.
An ophthalmologist-confirmed isolated episode should be referred to a consultant neurologist, as recommended by NICE.
Steroid decisions depend on the diagnosis and functional severity; do not substitute a low-dose oral course for a prescribed high-dose relapse regimen.

02AetiologyUnderlying causes, associations and risk factors, with why each one matters.

Demyelinating inflammation

Immune-mediated damage to optic-nerve myelin can occur as an isolated event or with multiple sclerosis. The clinical episode and the associated neurological diagnosis require related but distinct assessment.

Other antibody-associated disorders

AQP4-associated neuromyelitis optica spectrum disorder and MOG-antibody-associated disease can involve the optic nerve. Severe, recurrent or bilateral presentations strengthen the need for directed specialist investigation.

Infection and systemic inflammation

Selected infections and inflammatory disorders can cause optic neuropathy with an inflammatory appearance. Exposure history, systemic findings and imaging guide investigation and disease-specific treatment.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.

1
Impaired neural conduction
Inflammation and myelin injury interfere with transmission along optic-nerve fibres. This can impair brightness, colour, contrast and central visual function in combinations not fully captured by acuity alone.
2
Anterior or retrobulbar involvement
Inflammation at the optic nerve head can produce disc swelling, while more posterior involvement leaves the disc initially normal. Location explains why fundal appearance alone is insufficient.
3
Recovery and residual axonal injury
Inflammation can settle and conduction improve over time, but axonal injury may leave persistent functional or structural deficits. Recovery varies according to the underlying disease and episode severity.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.

Optic-nerve functional pattern

Reduced acuity, disproportionate colour or contrast impairment and an afferent pupil defect suggest optic-nerve dysfunction, although no single finding identifies the inflammatory cause.

Movement-related discomfort

Pain on eye movement is common in typical disease and can precede or accompany visual reduction; absence of pain should prompt reconsideration rather than automatic exclusion.

Normal or swollen disc

Retrobulbar inflammation can leave the disc apparently normal during the acute episode, whereas anterior involvement produces swelling; examine the entire eye for competing pathology.

Features beyond a typical episode

Bilateral involvement, severe or repeated attacks, unusual disc findings, systemic illness or limited recovery warrants investigation for alternative inflammatory, infectious or compressive causes.

Red flags requiring action

Severe bilateral loss, marked disc swelling, unusual neurological findings or poor early recovery requires urgent assessment for an atypical inflammatory or other optic neuropathy.
Sudden painless visual loss, an older age at onset or symptoms of giant-cell arteritis requires a different urgent diagnostic pathway.
New weakness, sensory change, bladder disturbance or other focal neurological symptoms should be communicated with the visual presentation.

05InvestigationsWhat to request, why it matters and how to interpret it.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
Acuity, colour vision, pupils and visual fieldsFirst step
Why
Document the pattern and baseline severity of optic dysfunction.
Interpretation and limitations
Compare each eye and record any central or other field deficit; use repeated functional measurements to judge recovery rather than relying on disc appearance alone.
02
Dilated ocular examination and selected OCT
Why
Assess the disc, retina and alternative causes of visual loss.
Interpretation and limitations
OCT can document structural change but a normal early scan does not exclude retrobulbar inflammation, and later thinning does not by itself establish the original cause.
03
MRI brain and orbits with an appropriate optic-nerve protocol
Why
Assess optic-nerve inflammation, compression and associated cerebral lesions.
Interpretation and limitations
Contrast-enhanced orbital sequences may demonstrate inflammation; brain lesions inform neurological assessment, but an isolated optic-neuritis episode does not automatically establish multiple sclerosis.
04
Targeted serum and other investigations
Why
Investigate atypical disease or a specific suspected systemic cause.
Interpretation and limitations
Neurology may request AQP4-IgG, MOG-IgG or directed inflammatory and infection testing according to the phenotype; indiscriminate testing without clinical interpretation can mislead.

06Differential diagnosisRealistic alternatives and the features that help distinguish them.

Ischaemic optic neuropathy

Abrupt often painless loss, an older patient and a swollen disc raise concern for ischaemic disease. Symptoms of giant-cell arteritis require immediate attention to an arteritic cause.

Compressive optic neuropathy

Progressive or atypical visual dysfunction can arise from a lesion affecting the optic nerve or adjacent structures. Appropriate orbital and brain imaging helps assess this possibility.

Retinal or macular pathology

Retinal disease can produce central blur, field loss or impaired visual quality. Examination of the retina and appropriate imaging prevents an afferent visual complaint from being mislocalised.

07ManagementImmediate care, first-line treatment, alternatives and escalation.

01Initial assessmentConfirm the affected structure and urgencyFirst stepA patient develops new visual loss with a possible optic-nerve pattern.

1Measure vision and pupils, ask about movement-related pain and neurological symptoms, and arrange urgent ophthalmic examination.
2Check for retinal, corneal, vascular or compressive alternatives, including giant-cell arteritis when age and symptoms make it plausible.
3Communicate severe, bilateral or atypical findings promptly to neuro-ophthalmology and neurology so investigation and treatment proceed at an appropriate pace.

02Typical or MS-associated episodeAgree investigation and a proportionate treatment planSpecialist assessment supports typical optic neuritis or a confirmed multiple-sclerosis relapse affecting vision.

1Discuss functional impact, expected recovery, steroid benefits and medical risks with the specialist and the patient.
2For an isolated ophthalmologist-confirmed episode, arrange consultant neurological assessment and the indicated MRI rather than assuming a diagnosis of multiple sclerosis.
3If a functionally significant MS relapse is selected for treatment, use the NICE high-dose regimen and ensure there is an explicit follow-up and adverse-effect plan.

03Atypical or resistant diseaseEscalate the underlying-cause assessmentEscalationVisual loss is unusually severe, bilateral, recurrent or failing to recover as expected.

1Reconsider AQP4-associated disease, MOG-associated disease, infection, systemic inflammation and a structural lesion using the clinical and imaging findings.
2Seek urgent specialist treatment decisions; more intensive immunotherapy or plasma exchange may be needed for selected severe inflammatory disease.
3Do not allow a reassuring expectation derived from typical optic neuritis to delay treatment of an eye with progressive or sustained severe dysfunction.

Key medicines and prescribing safety1 treatment · regimens, roles and cautions

Accelerates recovery from selected functionally significant inflammatory MS relapses, including an appropriately assessed visual relapse.

Methylprednisolone for a confirmed MS relapse

NICE recommends oral methylprednisolone 500 mg once daily for five days when an MS relapse is selected for treatment. Intravenous methylprednisolone 1 g daily for three to five days is an alternative when oral treatment fails or is not tolerated, or admission is needed for severity or monitoring.

Discuss the diagnosis and treatment with an MS specialist, assess infection and relevant diabetes or psychological risk, and explain sleep and mood effects. This is not a universal regimen for every optic neuropathy; do not issue spare courses for unsupervised future use.

08ComplicationsImportant consequences, why they occur and why they matter clinically.

Persistent visual dysfunction

Reduced contrast, altered colour perception or a residual field defect can remain after acuity improves. Functional questioning and rehabilitation address deficits that a reassuring chart result may overlook.

Recurrent inflammatory episodes

Further optic-nerve attacks can occur in several inflammatory disorders. Recognising the associated condition matters because some patients need a strategy to reduce future disease activity.

Treatment-related adverse effects

High-dose corticosteroids can disturb glucose control, mood and sleep and may worsen infection. Treatment decisions and monitoring should reflect the patient's comorbidities and the confirmed inflammatory indication.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.

Document recovery of acuity, colour discrimination, contrast-related difficulties and fields, including problems that remain despite improvement on a letter chart.
Review an unexpectedly poor or worsening course promptly and reconsider the diagnosis instead of repeatedly reassuring from the original label.
Ensure neurological referral and MRI results are followed through after an isolated episode, even when the patient reports substantial visual recovery.
During high-dose steroid treatment, assess relevant glucose, mood, sleep, infection and other individual risks, with a clear contact route for significant adverse effects.
Discuss work, driving and practical visual limitations according to measured function, and arrange rehabilitation or optical support for persistent deficits.

10Special situationsVariants, exceptions and circumstances that change the usual approach.

Acuity is only one outcome

A patient may recover good chart acuity while colours, contrast or sustained visual tasks remain abnormal. Ask about these differences when explaining the course and assessing function.

Heat-related symptoms need context

Previously injured demyelinated pathways can function less effectively with heat or exertion. Brief fluctuation does not automatically establish a fresh inflammatory relapse, but sustained new loss needs assessment.

Oral treatment is dose-specific

Evidence against conventional low-dose oral prednisone alone must not be misread as a ban on all oral steroids. NICE recommends a defined high-dose oral methylprednisolone course for selected MS relapses.

A neurological diagnosis needs its own criteria

Optic neuritis can be a presenting feature of multiple sclerosis or another inflammatory disease, but the optic episode alone does not settle that diagnosis or its long-term treatment.

11Common pitfallsFrequent interpretation and management errors.

01
Excluding optic neuritis because the optic disc looks normal, without testing colour vision, pupils and fields.
02
Treating every episode as typical demyelination despite bilateral profound loss, marked swelling or an unexpectedly poor course.
03
Starting an empirical low-dose oral steroid course without establishing the diagnosis and appropriate specialist regimen.
04
Cancelling neurological assessment after visual improvement and missing an opportunity to evaluate associated central nervous system disease.